Cargando…
Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial
Background: To determine the applicability and sensitivity of a urine self-test to detect gluten-immunogenic-peptides (GIP) in daily-life for patients with coeliac disease and correlate the test results with reported symptoms. Methods: We performed a prospective double-blinded placebo-controlled stu...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105321/ https://www.ncbi.nlm.nih.gov/pubmed/35565738 http://dx.doi.org/10.3390/nu14091771 |
_version_ | 1784708011937234944 |
---|---|
author | Burger, Jordy P. W. van Lochem, Ellen G. Roovers, Elisabeth A. Drenth, Joost P. H. Wahab, Peter J. |
author_facet | Burger, Jordy P. W. van Lochem, Ellen G. Roovers, Elisabeth A. Drenth, Joost P. H. Wahab, Peter J. |
author_sort | Burger, Jordy P. W. |
collection | PubMed |
description | Background: To determine the applicability and sensitivity of a urine self-test to detect gluten-immunogenic-peptides (GIP) in daily-life for patients with coeliac disease and correlate the test results with reported symptoms. Methods: We performed a prospective double-blinded placebo-controlled study, including adults with coeliac disease adhering to a strictly gluten-free diet. Patients were administered gluten in test-cycles of ascending doses of 50, 100, 200, and 500 mg alternated with placebo. Urine portions from 2, 5–17 h after the ingestion were collected and analyzed for GIP using the iVYCHECK-GIP-Urine rapid lateral flow test. Patients completed a diary mapping symptoms (nausea, bloating, diarrhea, abdominal pain, and lower level of energy). Results: We enrolled 15 patients and 7 received all 4 cycles with increasing gluten dosing. GIP was detected from urine in 47% of the patients receiving 50 mg gluten and in 86% with 500 mg gluten. We detected GIP in 20–50% of urine samples after placebo. There was no correlation between symptoms, gluten administration and/or GIP in urine. Conclusions: Gluten intake, even with a dose as low as 50 mg, leads to detectable urinary GIP concentrations. There is no correlation of coeliac disease ascribed symptoms with detection of urinary GIP. |
format | Online Article Text |
id | pubmed-9105321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91053212022-05-14 Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial Burger, Jordy P. W. van Lochem, Ellen G. Roovers, Elisabeth A. Drenth, Joost P. H. Wahab, Peter J. Nutrients Article Background: To determine the applicability and sensitivity of a urine self-test to detect gluten-immunogenic-peptides (GIP) in daily-life for patients with coeliac disease and correlate the test results with reported symptoms. Methods: We performed a prospective double-blinded placebo-controlled study, including adults with coeliac disease adhering to a strictly gluten-free diet. Patients were administered gluten in test-cycles of ascending doses of 50, 100, 200, and 500 mg alternated with placebo. Urine portions from 2, 5–17 h after the ingestion were collected and analyzed for GIP using the iVYCHECK-GIP-Urine rapid lateral flow test. Patients completed a diary mapping symptoms (nausea, bloating, diarrhea, abdominal pain, and lower level of energy). Results: We enrolled 15 patients and 7 received all 4 cycles with increasing gluten dosing. GIP was detected from urine in 47% of the patients receiving 50 mg gluten and in 86% with 500 mg gluten. We detected GIP in 20–50% of urine samples after placebo. There was no correlation between symptoms, gluten administration and/or GIP in urine. Conclusions: Gluten intake, even with a dose as low as 50 mg, leads to detectable urinary GIP concentrations. There is no correlation of coeliac disease ascribed symptoms with detection of urinary GIP. MDPI 2022-04-23 /pmc/articles/PMC9105321/ /pubmed/35565738 http://dx.doi.org/10.3390/nu14091771 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Burger, Jordy P. W. van Lochem, Ellen G. Roovers, Elisabeth A. Drenth, Joost P. H. Wahab, Peter J. Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial |
title | Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial |
title_full | Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial |
title_fullStr | Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial |
title_full_unstemmed | Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial |
title_short | Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial |
title_sort | dose-escalating (50–500 mg) gluten administration leads to detectable gluten-immunogenic-peptides in urine of patients with coeliac disease which is unrelated to symptoms, a placebo controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105321/ https://www.ncbi.nlm.nih.gov/pubmed/35565738 http://dx.doi.org/10.3390/nu14091771 |
work_keys_str_mv | AT burgerjordypw doseescalating50500mgglutenadministrationleadstodetectableglutenimmunogenicpeptidesinurineofpatientswithcoeliacdiseasewhichisunrelatedtosymptomsaplacebocontrolledtrial AT vanlochemelleng doseescalating50500mgglutenadministrationleadstodetectableglutenimmunogenicpeptidesinurineofpatientswithcoeliacdiseasewhichisunrelatedtosymptomsaplacebocontrolledtrial AT rooverselisabetha doseescalating50500mgglutenadministrationleadstodetectableglutenimmunogenicpeptidesinurineofpatientswithcoeliacdiseasewhichisunrelatedtosymptomsaplacebocontrolledtrial AT drenthjoostph doseescalating50500mgglutenadministrationleadstodetectableglutenimmunogenicpeptidesinurineofpatientswithcoeliacdiseasewhichisunrelatedtosymptomsaplacebocontrolledtrial AT wahabpeterj doseescalating50500mgglutenadministrationleadstodetectableglutenimmunogenicpeptidesinurineofpatientswithcoeliacdiseasewhichisunrelatedtosymptomsaplacebocontrolledtrial |